Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Efficacy of Astatine-211 radioimmunotherapy of Multiple Myeloma using an anti-mCD138 monoclonal antibody in a syngeneic murine model

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Contributors:
      Nuclear Oncology (CRCINA-ÉQUIPE 13); Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA); Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre Hospitalier Universitaire de Nantes (CHU Nantes)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE); Université de Nantes (UN)-Université de Nantes (UN)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre Hospitalier Universitaire de Nantes (CHU Nantes)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE); Université de Nantes (UN)-Université de Nantes (UN); Service de Médecine Nucléaire Nantes; Hôpital Laennec; École nationale vétérinaire, agroalimentaire et de l'alimentation Nantes-Atlantique (ONIRIS); GIP ARRONAX Nantes; Université de Nantes (UN); Laboratoire de physique subatomique et des technologies associées (SUBATECH); Université de Nantes - UFR des Sciences et des Techniques (UN UFR ST); Université de Nantes (UN)-Université de Nantes (UN)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-IMT Atlantique (IMT Atlantique); Institut Mines-Télécom Paris (IMT)-Institut Mines-Télécom Paris (IMT); Service de médecine nucléaire Saint-Herblain; Centre René Gauducheau-Institut Régional du Cancer Nantes-Atlantique (IRCNA)-Institut de Cancérologie de l'Ouest Angers/Nantes (UNICANCER/ICO); UNICANCER-UNICANCER
    • Publication Information:
      HAL CCSD
      Springer Verlag (Germany)
    • Publication Date:
      2018
    • Collection:
      Ecole des Mines de Nantes: HAL
    • Subject Terms:
    • Abstract:
      s of Annual Congress of the European Association of Nuclear Medicine October 13 – 17, 2018 Düsseldorf, Germany ; International audience ; Aim: Multiple myeloma is a B-cell malignancy of terminally differentiated plasma cells within the bone marrow. In spite of a very active search for new treatments, cure is almost never achieved. Alpha-radioimmunotherapy (RIT) is a new cancer treatment modality with tumour specific antibodies coupled to alpha particle-emitting radionuclides. CD138 (Syndecan-1) is found mainly in epithelial cells, but was shown to be expressed by most myeloma cells, both in human and in the mouse. The aim of the study was to evaluate the biodistribution, toxicity and efficacy of a rat Astatin-211-labelled anti-mouse CD138 antibody (211At-9E7.4) in a syngeneic mouse myeloma model. Materials and methods: C57BL/KaLwRij mice were grafted with 106 5T33 cells (murine myeloma cell line). Biodistribution was studied 15 min, 1h, 4h, 7h, 14h and 21h post-administration of 211At- 9E7.4 mAb. Toxicity (animal weight, blood cell counts and transaminase) and RIT efficacy were studied after a dose escalation using 370, 555, 740 and 1110 kBq of 211At-9E7.4 and two control groups 211At-IgG2a isotype control at 555 kBq or no treatment, 10 days after tumour engraftment. Results: Studies demonstrated a highly statistical survival benefit for the mice treated with 211At-9E7.4 at 555 kBq (p=0,0006) and 740 kBq (p<0,0001). At 555 kBq, the survival median was increase by 34 days and at 740 kBq 65% of the mice survived 160 days after engraftment. For treatments with 370 kBq with 211At-9E7.4 or 211At-isotype control at 555 kBq no significant benefit was observed. The higher activity with 1110 kBq of 211At-9E7.4 was clearly radiotoxic since mice were euthanized after a lost more than 30% of baseline weight 14 days after radiopharmaceutical injection. For the other groups, except transient decreases of leukocytes and red cells, no other toxicity could be demonstrated, especially on liver function, which does not ...
    • Relation:
      inserm-02341491; https://inserm.hal.science/inserm-02341491; https://inserm.hal.science/inserm-02341491/document; https://inserm.hal.science/inserm-02341491/file/OP-508%20EANM2018.pdf; WOS: WOS:000449266201132
    • Online Access:
      https://doi.org/10.1007/s00259-018-4148-3
      https://inserm.hal.science/inserm-02341491
      https://inserm.hal.science/inserm-02341491/document
      https://inserm.hal.science/inserm-02341491/file/OP-508%20EANM2018.pdf
    • Rights:
      info:eu-repo/semantics/OpenAccess
    • Accession Number:
      edsbas.1E846CEA